Login to Your Account

Analysts see field-position advantage over Teva

Missing the secondary endpoint in the phase III trial with NBI-98854 did little to dampen enthusiasm for Neurocrine Biosciences Inc.'s small-molecule vesicular monoamine transporter 2 (VMAT2) inhibitor against tardive dyskinesia (TD). more »

Our Habitat for All Things Science
Vaccines are bright spot in infectious disease fight

SAN DIEGO – Predictions at the International Conference on Antimicrobials and Chemotherapy and the International Congress of Chemotherapy (ICAAC/ICC) 2015 annual meeting tend to be of the dire sort, warning of a return to the pre-penicillin era. So it was a pleasant exception to listen to Glaxosmithkline plc's Rino Rappuoli brim with optimism during his plenary talk on challenges and opportunities of vaccines.



Partners in Focus